Leddy, Cecilia
7Genentech, Inc., South San Francisco, California.
2 papers on CoChat
Most cited papers
- Verified
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 59
- Verified
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., et al. (2012) · Cancer Chemotherapy and Pharmacology
Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research
Cited by 41
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free